BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21325458)

  • 1. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
    Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
    Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
    Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
    Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F
    Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
    Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment.
    Janse F; Donnez J; Anckaert E; de Jong FH; Fauser BC; Dolmans MM
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1136-44. PubMed ID: 21289248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
    Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
    Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
    Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
    Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels : anti-Müllerian hormone in poor responders in assisted reproductive treatment.
    Celik H; Bıldırcın D; Güven D; Cetinkaya MB; Alper T; Batuoğlu AS
    J Assist Reprod Genet; 2012 Aug; 29(8):797-802. PubMed ID: 22573035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Lee DY; Park YH; Lee JE; Choi D
    Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
    BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer.
    Anderson RA; Themmen AP; Al-Qahtani A; Groome NP; Cameron DA
    Hum Reprod; 2006 Oct; 21(10):2583-92. PubMed ID: 16820385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
    Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
    Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
    Anderson RA; Kelsey TW; Perdrix A; Olympios N; Duhamel O; Lambertini M; Clatot F
    Breast Cancer Res Treat; 2022 Apr; 192(2):273-282. PubMed ID: 34997365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age.
    Rosendahl M; Andersen CY; la Cour Freiesleben N; Juul A; Løssl K; Andersen AN
    Fertil Steril; 2010 Jun; 94(1):156-66. PubMed ID: 19342041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
    Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
    Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study.
    Ünal Ç; Ordu Ç; Özmen T; İlgun AS; Çelebi F; Baysal B; Özkurt E; Duymaz T; Erdoğan İyigün Z; Kurt S; Öztürk MA; Pilancı KN; Alço G; Yararbaş K; Kayan Tapan T; Güven DC; Soybir G; Özmen V
    Curr Oncol; 2023 Oct; 30(10):9217-9229. PubMed ID: 37887566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
    Wang S; Pei L; Hu T; Jia M; Wang S
    Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.